Karyopharm Therapeutics Inc (NASDAQ: KPTI) is 1.99% higher on its value in year-to-date trading and has touched a low of $0.62 and a high of $1.95 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KPTI stock was last observed hovering at around $0.89 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $0.88, the stock is 1.72% and 9.06% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.31 million and changing -0.50% at the moment leaves the stock -13.95% off its SMA200. KPTI registered 10.40% gain for a year compared to 6-month loss of -17.55%. The firm has a 50-day simple moving average (SMA 50) of $0.80688 and a 200-day simple moving average (SMA200) of $1.024975.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 3.23% gain in the last 1 month and extending the period to 3 months gives it a 8.91%, and is -10.87% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.38% over the week and 7.28% over the month.
Karyopharm Therapeutics Inc (KPTI) has around 325 employees, a market worth around $110.55M and $148.44M in sales. Profit margin for the company is -58.93%. Distance from 52-week low is 42.89% and -54.76% from its 52-week high. The company has generated returns on investments over the last 12 months (-282.69%).
The EPS is expected to grow by 43.09% this year
135.0 institutions hold shares in Karyopharm Therapeutics Inc (KPTI), with institutional investors hold 60.11% of the company’s shares. The shares outstanding are 114.92M, and float is at 114.06M with Short Float at 15.44%. Institutions hold 56.46% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 7.65 million shares valued at $6.64 million. The investor’s holdings represent 6.6299 of the KPTI Shares outstanding. As of 2024-06-30, the second largest holder is PALO ALTO INVESTORS LP with 5.1 million shares valued at $4.43 million to account for 4.4192 of the shares outstanding. The other top investors are EVERSEPT PARTNERS, LP which holds 4.99 million shares representing 4.3196 and valued at over $4.33 million, while ADAGE CAPITAL PARTNERS GP, L.L.C. holds 3.7416 of the shares totaling 4.32 million with a market value of $3.75 million.
Karyopharm Therapeutics Inc (KPTI) Insider Activity
The most recent transaction is an insider sale by Paulson Richard A., the company’s President and CEO. SEC filings show that Paulson Richard A. sold 3,675 shares of the company’s common stock on Nov 05 ’24 at a price of $0.91 per share for a total of $3346.0. Following the sale, the insider now owns 1.13 million shares.
Karyopharm Therapeutics Inc disclosed in a document filed with the SEC on Oct 04 ’24 that Paulson Richard A. (President and CEO) sold a total of 3,607 shares of the company’s common stock. The trade occurred on Oct 04 ’24 and was made at $0.88 per share for $3172.0. Following the transaction, the insider now directly holds 1.14 million shares of the KPTI stock.
Still, SEC filings show that on Sep 04 ’24, Mano Michael (SVP, General Counsel&Secretary) disposed off 3,971 shares at an average price of $0.72 for $2866.0. The insider now directly holds 273,881 shares of Karyopharm Therapeutics Inc (KPTI).
